David A. Zarling
Directeur Général chez Colby Pharmaceutical Co.
Profil
David A.
Zarling is the founder of Colby Pharmaceutical Co. Prior to that, he worked as the President & Chief Executive Officer of Pangene Corp.
and as a Program Director at SRI International.
He also served as an Adjunct Associate Professor at The University of California, San Francisco.
Zarling received his undergraduate and graduate degrees from Dartmouth College and an MBA from Pepperdine University.
He also holds a doctorate from Baylor College of Medicine.
Postes actifs de David A. Zarling
| Sociétés | Poste | Début |
|---|---|---|
Colby Pharmaceutical Co.
 Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Directeur Général | 01/01/2004 |
Anciens postes connus de David A. Zarling
| Sociétés | Poste | Fin |
|---|---|---|
SRI International
 SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Corporate Officer/Principal | - |
| The University of California, San Francisco | Corporate Officer/Principal | - |
Pangene Corp.
 Pangene Corp. Pharmaceuticals: MajorHealth Technology Pangene Corp. develops oncology drugs based on its DNA repair and recombination platform. The company is headquartered in Mountain View, CA. | President | - |
Formation de David A. Zarling
| Dartmouth College | Graduate Degree |
| Baylor College of Medicine | Doctorate Degree |
| Pepperdine University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Colby Pharmaceutical Co.
Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Health Technology |
Pangene Corp.
Pangene Corp. Pharmaceuticals: MajorHealth Technology Pangene Corp. develops oncology drugs based on its DNA repair and recombination platform. The company is headquartered in Mountain View, CA. | Health Technology |
SRI International
SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Commercial Services |
